Shopping Cart
- Remove All
- Your shopping cart is currently empty
BBDDL2059 is a selective covalent inhibitor of EZH2 with an IC50 of 1.5 nM against the EZH2-Y641F mutant, demonstrating nanomolar potency in inhibiting lymphoma cell proliferation, thereby proving its utility in anticancer research [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,670 | 8-10 weeks | |
50 mg | $2,180 | 8-10 weeks | |
100 mg | $2,800 | 8-10 weeks |
Description | BBDDL2059 is a selective covalent inhibitor of EZH2 with an IC50 of 1.5 nM against the EZH2-Y641F mutant, demonstrating nanomolar potency in inhibiting lymphoma cell proliferation, thereby proving its utility in anticancer research [1]. |
Targets&IC50 | EZH2 (Y641F):1.5 nM |
In vitro | BBDDL2059 (Compound 16) at concentrations ranging from 0-65 nM over 6 days inhibits the growth of KARPAS-422 and Pfeiffer cells [1]. Moreover, BBDDL2059 at doses between 0-1 µM for 48-96 hours suppresses EZH2 enzymatic activity and sustains long-term inhibition of EZH2 following washout [1]. |
In vivo | BBDDL2059 (Compound 16) demonstrated a pharmacokinetic profile in rats, with a half-life (T 1/2) of 0.28 hours following an intravenous dose of 3 mg/kg and an oral bioavailability (F%) of 0.05% at a 10 mg/kg oral dose [1]. The respective pharmacokinetic parameters for intravenous administration were a maximum concentration (Cmax) of 4886 ng/mL, an area under the curve (AUC0-last) of 11.1 h•ng/mL, a clearance (CL) of 161 mL•min^-1/kg^-1, and a steady-state volume of distribution (Vss) of 11.1 L/kg. The oral dose resulted in a Cmax of 29.5 ng/mL and an AUC0-last of 8.16 h•ng/mL [1]. |
Molecular Weight | 512.66 |
Formula | C27H36N4O4S |
Cas No. | 2691174-27-1 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.